BCYC
Price
$7.88
Change
+$0.07 (+0.90%)
Updated
Oct 24 closing price
Capitalization
546.14M
5 days until earnings call
Intraday Buy/Sell Signals
DNLI
Price
$15.96
Change
+$0.08 (+0.50%)
Updated
Oct 24 closing price
Capitalization
2.33B
5 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

BCYC vs DNLI

Header iconBCYC vs DNLI Comparison
Open Charts BCYC vs DNLIBanner chart's image
Bicycle Therapeutics
Price$7.88
Change+$0.07 (+0.90%)
Volume$268.3K
Capitalization546.14M
Denali Therapeutics
Price$15.96
Change+$0.08 (+0.50%)
Volume$1.07M
Capitalization2.33B
BCYC vs DNLI Comparison Chart in %
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCYC vs. DNLI commentary
Oct 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Hold and DNLI is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 25, 2025
Stock price -- (BCYC: $7.88 vs. DNLI: $15.96)
Brand notoriety: BCYC and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 99% vs. DNLI: 52%
Market capitalization -- BCYC: $546.14M vs. DNLI: $2.33B
BCYC [@Biotechnology] is valued at $546.14M. DNLI’s [@Biotechnology] market capitalization is $2.33B. The market cap for tickers in the [@Biotechnology] industry ranges from $108.04B to $0. The average market capitalization across the [@Biotechnology] industry is $2.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • BCYC’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, DNLI is a better buy in the long-term than BCYC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 5 TA indicator(s) are bullish while DNLI’s TA Score has 6 bullish TA indicator(s).

  • BCYC’s TA Score: 5 bullish, 5 bearish.
  • DNLI’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than BCYC.

Price Growth

BCYC (@Biotechnology) experienced а -3.55% price change this week, while DNLI (@Biotechnology) price change was -4.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.97%. For the same industry, the average monthly price growth was +11.13%, and the average quarterly price growth was +63.98%.

Reported Earning Dates

BCYC is expected to report earnings on Oct 30, 2025.

DNLI is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+0.97% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.33B) has a higher market cap than BCYC($546M). DNLI YTD gains are higher at: -21.688 vs. BCYC (-43.714). BCYC has higher annual earnings (EBITDA): -240.81M vs. DNLI (-521.52M). DNLI has more cash in the bank: 899M vs. BCYC (721M). BCYC has less debt than DNLI: BCYC (7.2M) vs DNLI (46.6M). BCYC has higher revenues than DNLI: BCYC (19.3M) vs DNLI (0).
BCYCDNLIBCYC / DNLI
Capitalization546M2.33B23%
EBITDA-240.81M-521.52M46%
Gain YTD-43.714-21.688202%
P/E RatioN/AN/A-
Revenue19.3M0-
Total Cash721M899M80%
Total Debt7.2M46.6M15%
FUNDAMENTALS RATINGS
BCYC vs DNLI: Fundamental Ratings
BCYC
DNLI
OUTLOOK RATING
1..100
7180
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9797
PRICE GROWTH RATING
1..100
6348
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (50) in the null industry is in the same range as DNLI (50) in the Biotechnology industry. This means that BCYC’s stock grew similarly to DNLI’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as DNLI (100) in the Biotechnology industry. This means that BCYC’s stock grew similarly to DNLI’s over the last 12 months.

BCYC's SMR Rating (97) in the null industry is in the same range as DNLI (97) in the Biotechnology industry. This means that BCYC’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's Price Growth Rating (48) in the Biotechnology industry is in the same range as BCYC (63) in the null industry. This means that DNLI’s stock grew similarly to BCYC’s over the last 12 months.

DNLI's P/E Growth Rating (100) in the Biotechnology industry is in the same range as BCYC (100) in the null industry. This means that DNLI’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCDNLI
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
75%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
72%
Advances
ODDS (%)
Bullish Trend 10 days ago
82%
Bullish Trend 11 days ago
76%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
85%
Aroon
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYCEX96.93N/A
N/A
Rydex Europe 1.25x Strategy C
DLACX16.77N/A
N/A
BNY Mellon Large Cap Equity Y
JDISX17.43N/A
N/A
JHancock Disciplined Value Intl R2
ANVRX10.66N/A
N/A
American Century Non-US Intrs Val R
VWYKX47.60N/A
N/A
Voya Small Cap Growth W

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with RPTX. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then RPTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+0.90%
RPTX - BCYC
55%
Loosely correlated
+1.55%
RGNX - BCYC
44%
Loosely correlated
+3.58%
NRIX - BCYC
44%
Loosely correlated
+6.63%
XNCR - BCYC
43%
Loosely correlated
+7.05%
AUTL - BCYC
43%
Loosely correlated
+2.00%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+0.50%
NRIX - DNLI
58%
Loosely correlated
+6.63%
ARWR - DNLI
56%
Loosely correlated
+1.74%
RGNX - DNLI
55%
Loosely correlated
+3.58%
BEAM - DNLI
55%
Loosely correlated
-0.85%
OCUL - DNLI
54%
Loosely correlated
+0.44%
More